knowledge -WSS

knowledge

author：explore 2025-09-14 18:28:07 - browse：13

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： How should state employee insurance handle Wegovy?

focus

WSS

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Better Therapeutics data on benefit with GLP

Bernie Sanders bashes nonprofit hospitals over their tax breaks

The a glaring gap in research on serious mental illness and primary care

Pharma showers House GOP doctor with campaign cash

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

entertainment

knowledge

hotspot

Peter Hotez and the public health issue of online harassment

A revolution in caring for preterm infants

Wildfire smoke exposes gaps in outdoor worker protections

How doctors and nurses shape Google's AI

23andMe had bad news about my health. I wish a person had delivered it

What's changing in Medicare's open enrollment this year?

Medical records are filled with copy

When waiting feels immoral: Empathy in the emergency department

How one medical school became remarkably diverse

When waiting feels immoral: Empathy in the emergency department

knowledge

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Female surgeons have lower rates of long

A revolution in caring for preterm infants

European regulators consider appeal over Amylyx ALS drug

FDA approves Sage Therapeutics’ rapid

Massive project maps cells in human brain in unprecedented detail

hotspot

focus

focus

explore